Nearly 12.5 million new cancer cases are diagnosed worldwide each year. Although new treatments have been developed, most new anticancer drugs that are effective outside the brain have failed in clinical trials against brain tumours, in part due to poor penetration across the blood-brain barrier and the blood-brain tumour barrier. This review will discuss the challenges of drug delivery across the blood-brain barrier/blood-brain tumour barrier to cancer cells, as well as progress made so far. This will include a biochemical modulation strategy that transiently opens the barrier to increase anticancer drug delivery selectively to brain tumours. It will also briefly discuss a quantitative non-invasive method to measure permeability changes and tumour response to treatment in the human brain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/17425247.3.4.499 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a Physiologically-Based Pharmacokinetic Model for Quantitative Interpretation of Transdermal Drug Delivery of Rotigotine, a Dopamine Agonist for Treating Parkinson's Disease.
Eur J Drug Metab Pharmacokinet
March 2025
College of Pharmacy, Sunchon National University, 255 Jungang-ro, Suncheon-si, Jeollanam-do, 57922, Republic of Korea.
Background And Objective: Rotigotine, a dopamine agonist, is used to treat Parkinson's disease and restless leg syndrome, with transdermal patches being the primary delivery method in clinical practice. However, quantitative information on the in vivo pharmacokinetics of rotigotine across various dosage regimens via transdermal administration remains limited, and this has been identified as a significant barrier to achieving precision medicine. This study aims to develop a novel physiologically-based systematic pharmacokinetic model tailored to rotigotine transdermal drug delivery.
View Article and Find Full Text PDFSelf-assembled injectable Icariin@ TiCTx/doxorubicin hydrogel preserving osteogenesis while synergizing photodynamic and chemodynamic therapy for osteosarcoma.
J Mater Sci Mater Med
March 2025
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Local therapy involving injectable hydrogel systems loaded with doxorubicin (DOX) has garnered significant attention in the realm of osteosarcoma (OS) research. Nevertheless, it has been noted that the local delivery of high-dose DOX exerts a pronounced inhibitory impact on osteogenesis, which is detrimental to the restoration of functional capabilities after OS treatment. To address this challenge, we have designed a self-assembled injectable hydrogel system that integrates photodynamic and chemodynamic therapy, aiming to enhance efficacy while mitigating adverse effects on osteogenic differentiation.
View Article and Find Full Text PDFSalutary effects of transdermal curcumin on multiple indices of health span in rodent models of normal aging and hypertension.
Geroscience
March 2025
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA.
Geroscience has helped to usher in a new and exciting era of aging drug development and evaluation of novel and repurposed agents, as well as natural compounds purported to target one or more aging hallmarks. Among the latter, curcumin has long been pursued as a promising strategy but has failed to provide convincing evidence in human trials. Oral intake is the typical route of administration tested for the vast majority of gerotherapeutic candidates, including curcumin, but efficacy is dependent upon good oral bioavailability and pharmacokinetics.
View Article and Find Full Text PDFProtective effect of histatin 5 and amphotericin B conjugated nanostructures in C. albicans challenged Swiss albino mice.
Naunyn Schmiedebergs Arch Pharmacol
March 2025
Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, 603103, Tamil Nadu, India.
This study explores the development of silica-gold nanostructures conjugated with histatin 5 (H5) and amphotericin B (AB) for the management of Candida albicans-induced candidiasis. H5 and AB were covalently attached to the silica-gold nanostructures (ASi-GN) using EDC-NHS chemistry, with fluorescent FITC labeling employed in a parallel experiment to study nanostructure localization. Characterization techniques, including UV-Vis spectroscopy, dynamic light scattering, zeta potential analysis, fluorescence spectroscopy, differential scanning calorimetry, thermogravimetric analysis, high-resolution transmission electron microscopy, atomic force microscopy, and drug release studies, confirmed the successful conjugation and stability of the nanostructures.
View Article and Find Full Text PDFA double-blind, randomized, placebo-controlled study to evaluate the efficacy of Oxybutynin Chloride Extended-Release tablets on the double-J stent related symptoms following uncomplicated ureteroscopic lithotripsy.
Urolithiasis
March 2025
Division of Urology, Department of Surgery, Yonghe Cardinal Tien Hospital, New Taipei City, Taiwan.
To evaluate the effects of Oxybutynin Chloride Extended-Release Tablets (Oxbu) on double-J stent-related symptoms following uncomplicated ureterosocpic lithotripsy (URSL). This is a double-blind, randomized, placebo-controlled study with a total of 120 subjects with ureteral calculi receiving double-J stent insertion following URSL. Subjects who meet the inclusion and exclusion criteria will be randomly assigned to Oxbu or placebo group.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!